# Claroty

publishes a documented case study of an Italian pharmaceutical multinational securing critical production plans and maintaining regulatory compliance without interrupting production, alongside dedicated guidance on securing OT in pharmaceutical and biotechnology.


Source: https://bioecon.ru/companies/claroty/
Updated: 2026-08-15

- Страна: United States

## Проверяемые факты

| Факт | Значение | Источник |
| --- | --- | --- |
| Финансирование | 510.1 million евро в 2024 году | https://blog.claroty.com/resources/case-studies/a-prescription-for-protection, https://claroty.com/resources/case-studies/a-prescription-for-protection, https://it.claroty.com/resources/case-studies/a-prescription-for-protection, https://social.claroty.com/resources/case-studies/a-prescription-for-protection, https://www.casestudies.com/company/claroty/case-study/fidia-farmaceutici-secures-1700-employee-operations-with-claroty-and-3-year-nis2-readiness |
| Мощность | 50 million/год, 115 million/год, 6 million/год, 75 million/год, 20 million пластырей/год, 35+ million полотенец/год, 3+ million губных помад/год | https://www.fidiapharma.com/our-innovation/sites/, https://www.fidiapharma.com/wp-content/uploads/2025/05/Fidia-Consolidated-financial-statements-2024.pdf |
| Сертификация | ISO 14001, ISO 9001, ISO 13485, GMP, ISO 22716 | https://www.fidiapharma.com/our-innovation/sites/, https://www.fidiapharma.com/wp-content/uploads/2025/05/Fidia-Consolidated-financial-statements-2024.pdf |
| Регуляторное одобрение | разрешено AIFA | https://claroty.com/resources/case-studies/a-prescription-for-protection, https://www.fidiapharma.com/our-innovation/sites/, https://www.fidiapharma.com/wp-content/uploads/2025/05/Fidia-Consolidated-financial-statements-2024.pdf |
| Производственная площадка | Абано-Терме (Падуя), Ното (Сиракузы), Падерно-Дуньяно (Милан), Монте-Джиберто (Фермо) | https://www.fidiapharma.com/our-innovation/sites/, https://www.fidiapharma.com/wp-content/uploads/2025/05/Fidia-Consolidated-financial-statements-2024.pdf |
| Численность | 1,700 сотрудников по всему миру | https://blog.claroty.com/resources/case-studies/a-prescription-for-protection, https://claroty.com/resources/case-studies/a-prescription-for-protection, https://it.claroty.com/resources/case-studies/a-prescription-for-protection, https://social.claroty.com/resources/case-studies/a-prescription-for-protection, https://www.casestudies.com/company/claroty/case-study/fidia-farmaceutici-secures-1700-employee-operations-with-claroty-and-3-year-nis2-readiness, https://www.fidiapharma.ro/wp-content/uploads/2024/06/Corporate_Press_kit_ENG_MAY2024.pdf |
| Выручка | 510.1 million евро в 2024 году | https://blog.claroty.com/resources/case-studies/a-prescription-for-protection, https://claroty.com/resources/case-studies/a-prescription-for-protection, https://it.claroty.com/resources/case-studies/a-prescription-for-protection, https://social.claroty.com/resources/case-studies/a-prescription-for-protection, https://www.fidiapharma.ro/wp-content/uploads/2024/06/Corporate_Press_kit_ENG_MAY2024.pdf |

Независимые источники: casestudies.com, fidiapharma.com, fidiapharma.ro

## Технологии

- [Биокибербезопасность](https://bioecon.ru/technology/bio-cybersecurity/)